Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aspreva Pharmaceuticals Corp.

Division of Vifor Pharma Group

Latest From Aspreva Pharmaceuticals Corp.

Deals Of The Week: Alnylam/The Medicines Co., Inspiration/Cangene, Pfizer/OxOnc

Biogen brings Tysabri fully in-house by using off-shore cash to compensate Irish partner Elan. Plus, the week in biopharma deal-making.

BioPharmaceutical Deals

Protox appoints chief financial officer

Protox Therapeutics, a company specialising in the development of receptor targeted fusion proteins, has appointed John Parkinson chief financial officer. Mr Parkinson previously held the role of vice-president, finance at Aspreva Pharmaceuticals. He takes over his new role from David Swetlow, vice president of finance and operations, who has resigned.


Market Insight - Drug repositioning: a new strategy for success

The repositioning of drugs for new clinical indications is becoming an increasingly prominent development strategy because it can reduce development risk as well as both the time and investment required to bring a product to market. Previously exclusive to pharmaceutical companies working to expand the applications of their marketed drugs, repositioning (also known as repurposing, reprofiling, therapeutic switching, or developing 'second use' indications) has emerged as an industry in its own right, encompassing both technology and drug companies. Today, companies involved in repositioning are charging for their services, establishing collaborative agreements and using the strategy to develop their own pipelines.

Gastrointestinal Metabolic Disorders

Where Are They Now: A Quiet Year

Last year was a quiet one for the biopharma and medical device companies on 2007's A-List, even if the trends we pointed out were validated by continued and increased VC interest. None of the firms were acquired and only one, Aegerion Pharmaceuticals, filed to go public.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Vifor Pharma Group
  • Senior Management
  • Bruce Cousins, CFO & EVP
    Paul Brennan, SVP, Bus. Dev.
    Usman Azam, MD, EVP & CMO
  • Contact Info
  • Aspreva Pharmaceuticals Corp.
    Phone: (250) 744-2488
    #1203, 4464 Markham Street
    Victoria, V8Z 7X8